SGSamuel F. Gerard

Samuel F. Gerard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Samuel F. Gerard has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Intrinsic curvature of the HIV-1 CA hexamer underlies capsid topology and interaction with cyclophilin A

    by Tao Ni, Samuel Gerard, Gongpu Zhao, Kyle Dent, Jiying Ning, Jing Zhou, Jiong Shi, Jordan Anderson-Daniels, Wen Li, Sooin Jang, et al.

    The mature retrovirus capsid consists of a variably curved lattice of capsid protein (CA) hexamers and pentamers. High-resolution structures of the curved assembly, or in complex with host factors, have not been available. By devising cryo-EM methodologies for exceedingly flexible and pleomorphic assemblies, we have determined cryo-EM structures of apo-CA hexamers and in complex with cyclophilin A (CypA) at near-atomic resolutions. The CA hexamers are intrinsically curved, flexible and asymmetric, revealing the capsomere and not the previously touted dimer or trimer interfaces as the key contributor to capsid curvature. CypA recognizes specific geometries of the curved lattice, simultaneously interacting with three CA protomers from adjacent hexamers via two noncanonical interfaces, thus stabilizing the capsid. By determining multiple structures from various helical symmetries, we further revealed the essential plasticity of the CA molecule, which allows formation of continuously curved conical capsids and the mechanism of capsid pattern sensing by CypA.


  • Open Access

    Structure of the Inhibited State of the Sec Translocon

    by Samuel F. Gérard, Belinda S. Hall, Afroditi M. Zaki, Katherine A. Corfield, Peter U. Mayerhofer, Catia Costa, Daniel K. Whelligan, Philip C. Biggin, Rachel E. Simmonds, Matthew K. Higgins


  • Open Access

    Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody

    by Thomas. A. Rawlinson, Natalie M. Barber, Franziska Mohring, Jee Sun Cho, Varakorn Kosaisavee, Samuel F. Gérard, Daniel G. W. Alanine, Geneviève M. Labbé, Sean C. Elias, Sarah E. Silk, et al.

    The most widespread form of malaria is caused by Plasmodium vivax. To replicate, this parasite must invade immature red blood cells through a process requiring interaction of the P. vivax Duffy binding protein (PvDBP) with its human receptor, the Duffy antigen receptor for chemokines. Naturally acquired antibodies that inhibit this interaction associate with clinical immunity, suggesting PvDBP as a leading candidate for inclusion in a vaccine to prevent malaria due to P. vivax. Here, we isolated a panel of monoclonal antibodies from human volunteers immunized in a clinical vaccine trial of PvDBP. We screened their ability to prevent PvDBP from binding to the Duffy antigen receptor for chemokines, and their capacity to block red blood cell invasion by a transgenic Plasmodium knowlesi parasite genetically modified to express PvDBP and to prevent reticulocyte invasion by multiple clinical isolates of P. vivax. This identified a broadly neutralizing human monoclonal antibody that inhibited invasion of all tested strains of P. vivax. Finally, we determined the structure of a complex of this antibody bound to PvDBP, indicating the molecular basis for inhibition. These findings will guide future vaccine design strategies and open up possibilities for testing the prophylactic use of such an antibody.


  • Cep120 promotes microtubule formation through a unique tubulin binding C2 domain

    by Ashwani Sharma, Samuel F. Gerard, Natacha Olieric, Michel O. Steinmetz